Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rVSVΔG-MARV (Angola) GP
- Development stage
- Phase 1
- Lead developer
- Public Health Vaccines
- Modality
- Recombinant Proteins and Enzymes, Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rVSVΔG-MARV (Angola) GP is a recombinant vesicular stomatitis virus-based vaccine candidate designed to prevent infection by the Marburg virus, specifically the Angola strain. The vaccine uses a live-attenuated VSV vector in which the gene for VSV glycoprotein is replaced with the gene encoding the glycoprotein of Marburg virus (GP). This enables expression of MARV GP on the surface of infected cells and induces robust humoral and cellular immune responses against Marburg virus. The platform is similar to that used for Ervebo, an approved Ebola Zaire vaccine. Preclinical studies have shown that a single intramuscular dose provides rapid and complete protection in nonhuman primates against lethal challenge with MARV Angola. The vaccine is being developed as both a prophylactic and post-exposure countermeasure for outbreaks and bioterrorism threats[1][2][3][4][5].
- Brand names
- PHV01PHV-01PHV 01
- Other names
- rVSV-N4CT1-MARV-GPrVSV-N-4CT1-MARV-GPrVSV-N 4CT1-MARV-GPrecombinant vesicular stomatitis virus Marburg glycoprotein vaccine (Angola)Vesiculovax
02
Targets
PYG (Glycogen phosphorylase)
Beyond the preview
Go deeper on rVSVΔG-MARV (Angola) GP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rVSVΔG-MARV (Angola) GP.